Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 42Gastrointestinal 3Head & Neck 2Gynecologic 2Thoracic 1Other solid neoplasm 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × dalpiciclib × Head & Neck × Clear all
NCT06109207 2024-07-23

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

West China Hospital

Phase 1 Recruiting
6 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06199271 2024-01-22

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Sichuan University

Phase 2 Not yet recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡